Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM. Sofosbuvir (PSI-7977) is a uridine nucleotide analog as HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir (PSI-7977) is a more potent inhibitor of HCV RNA replication than PSI-7976. When CatA is incubated with PSI-7977 or PSI-7976, ~18-fold more PSI-352707 is formed when PSI-7977 is the substrate compared with PSI-7976, and the catalytic efficiency for PSI-7977 with CatA is ~30-fold higher than that for PSI-7976. However, CES1 preferentially hydrolyzes PSI-7976 over PSI-7977. Incubating clone A cells with PSI-7977 results in a higher concentration of PSI-7409 than that with PSI-7976. NS5B polymerase S282T mutation but not S96T mutation is resistant to PSI-7977 with EC90 of 7.8 μM. PSI-7977 has no cytotoxicity against Huh7, HepG2, BxPC3, and CEM cells even at concentrations up to 100 μM. PSI-7977 is active against genotype (GT) 1a, 1b, and 2a (strain JFH-1) replicons and chimeric replicons containing GT 2a (strain J6), 2b, and 3a NS5B polymerase. Cross-resistance studies using GT 1b replicons confirme that the S282T change conferres resistance to PSI-7977. Data from the JFH-1 replicon variants show that amino acid changes within the finger and palm domains together with S282T are required to confer resistance to PSI-7977, while the mutations on the thumb domain serve to enhance the replication capacity of the S282T replicons. PSI-7977 is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C.
Cell Experiment | |
---|---|
Cell lines | Huh7, HepG2, BxPC3, and CEM |
Preparation method | Exposing cells to various concentrations of PSI-7977 for 8 days. At the end of the growth period, adding MTS dye from the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit to each well, and incubating the plate for an additional 2 hours. Read the absorbance at 490 nm with a Victor3 plate reader using themedium only controlwells as blanks. determing the 50% inhibition value (IC50) by comparing the absorbance in wells containing cells and PSI-7977 to untreated cell control wells. |
Concentrations | Dissolved in DMSO, final concentrations ~100 μM |
Incubation time | 8 days |
Animal Experiment | |
---|---|
Animal models | |
Formulation | |
Dosages | |
Administration |
Molecular Weight | 529.45 |
Formula | C22H29FN3O9P |
CAS Number | 1190307-88-0 |
Solubility (25°C) | DMSO 80 mg/mL Water 9 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related HCV Protease Products |
---|
Hepatitis C Virus S5A/5B
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. |
Ac-D-DGla-LI-Cha-C
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. |
Ac-EEVVAC-pNA
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. |
Hepatitis Virus C NS3 Protease Inhibitor 2
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM. |
Mipomersen
Mipomersen is a 20-base gapmer (antisense oligonucleotide) that inhibits apolipoprotein B (apoB) and lowers LDL, which can be used in studies related to hyperlipidemia. In addition, Mipomersen has anti-HCV activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.